MiNK Therapeutics Relocates HQ to New York
Ticker: INKT · Form: 8-K · Filed: Sep 29, 2025 · CIK: 1840229
Sentiment: neutral
Topics: corporate-actions, address-change
TL;DR
MiNK Therapeutics moved its HQ to NYC, formerly AgenTus Therapeutics.
AI Summary
MiNK Therapeutics, Inc. announced on September 23, 2025, a change in its principal executive offices to 149 Fifth Avenue, Suite 500, New York, NY 10010. The company also reported its former name was AgenTus Therapeutics, Inc., with a name change effective January 12, 2021. This filing is a current report under Section 13 or 15(d) of the Securities Exchange Act of 1934.
Why It Matters
A change in principal executive offices can signal strategic shifts, operational changes, or proximity to key partners or talent pools.
Risk Assessment
Risk Level: low — This filing primarily concerns a change in business address and historical company name, with no immediate financial or operational risks indicated.
Key Players & Entities
- MiNK Therapeutics, Inc. (company) — Registrant
- AgenTus Therapeutics, Inc. (company) — Former company name
- 149 Fifth Avenue, Suite 500, New York, NY 10010 (location) — New Principal Executive Offices
- January 12, 2021 (date) — Date of name change
- September 23, 2025 (date) — Date of earliest event reported
FAQ
What is the new address for MiNK Therapeutics, Inc.'s principal executive offices?
The new address is 149 Fifth Avenue, Suite 500, New York, NY 10010.
When was the name change from AgenTus Therapeutics, Inc. to MiNK Therapeutics, Inc. effective?
The name change was effective on January 12, 2021.
What is the filing date for this 8-K report?
The filing date is September 29, 2025, and the earliest event reported is September 23, 2025.
Under which section of the Securities Exchange Act is this report filed?
This report is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
What was MiNK Therapeutics, Inc.'s former company name?
MiNK Therapeutics, Inc.'s former company name was AgenTus Therapeutics, Inc.
Filing Stats: 612 words · 2 min read · ~2 pages · Grade level 9.8 · Accepted 2025-09-29 09:14:53
Key Financial Figures
- $0.00001 — ch registered Common Stock, par value $0.00001 per share INKT The Nasdaq Stock Mar
Filing Documents
- inkt-20250923.htm (8-K) — 43KB
- inkt-ex99_1.htm (EX-99.1) — 15KB
- 0001193125-25-221863.txt ( ) — 169KB
- inkt-20250923.xsd (EX-101.SCH) — 25KB
- inkt-20250923_htm.xml (XML) — 5KB
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits 99.1 Press Release dated September 29, 2025
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: September 29, 2025 By: /s/ Jennifer S. Buell, Ph.D. Jennifer S. Buell, Ph.D., CEO